Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have, therefore, investigated QIP-MS to monitor peripheral resid...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:311095 |
| Acceso en línea: | https://ddd.uab.cat/record/311095 https://dx.doi.org/urn:doi:10.3324/haematol.2024.285742 |
| Access Level: | acceso abierto |
| Palabra clave: | Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Female Humans Male Mass Spectrometry Middle Aged Multiple Myeloma Myeloma Proteins Neoplasm, Residual Prognosis Smoldering Multiple Myeloma Treatment Outcome |
| id |
ES_f5e026fba6ce43daf425b5bdd366e90d |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:311095 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial |
| title |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial |
| spellingShingle |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial Puig, Noemí|||0000-0001-7535-3861 Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Female Humans Male Mass Spectrometry Middle Aged Multiple Myeloma Myeloma Proteins Neoplasm, Residual Prognosis Smoldering Multiple Myeloma Treatment Outcome |
| title_short |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial |
| title_full |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial |
| title_fullStr |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial |
| title_full_unstemmed |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial |
| title_sort |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial |
| dc.creator.none.fl_str_mv |
Puig, Noemí|||0000-0001-7535-3861 Agulló, Cristina Contreras, Teresa Pérez, José Juan Aires, Irene Calasanz, M.J.|||0000-0002-0374-3008 García-Sanz, Ramón|||0000-0003-4120-2787 Castro, Sergio Martínez-López, Joaquín|||0000-0001-7908-0063 Rodriguez-Otero, Paula|||0000-0001-5236-7785 González-Calle, Verónica|||0000-0002-5493-6707 González, Marta S. Oriol, Albert|||0000-0001-6804-2221 Gutierrez, Norma|||0000-0001-5834-9510 Ríos-Tamayo, Rafael|||0000-0001-8193-1402 Rosiñol, Laura|||0000-0002-2534-9239 Álvarez, Miguel Ángel Bargay, Joan|||0000-0002-6739-3916 Gonzalez-Rodriguez, Ana P. Alegre, Adrian|||0000-0002-2423-822X Escalante, Fernando|||0000-0003-4501-9066 Iñigo Rodríguez, María Belén de la Rubia, Javier|||0000-0002-8354-768X Teruel, Ana Isabel|||0000-0003-1559-7607 De Arriba, Felipe|||0000-0002-4451-1318 Palomera, Luis|||0000-0003-0359-7191 Hernández, Miguel Teodoro|||0000-0002-6576-7881 López-Jiménez, Javier Reinoso, Marta García-Mateo, Aránzazu Ocio, Enrique M.|||0000-0002-5765-0085 Bladé Creixenti, Juan|||0000-0002-4563-3405 Lahuerta, J. J.|||0000-0002-3393-9570 Cedena, María Teresa|||0000-0001-5851-3720 Paiva, Bruno|||0000-0003-1977-3815 San Miguel, Jesús F. Mateos, M. V.|||0000-0003-2390-1218 |
| author |
Puig, Noemí|||0000-0001-7535-3861 |
| author_facet |
Puig, Noemí|||0000-0001-7535-3861 Agulló, Cristina Contreras, Teresa Pérez, José Juan Aires, Irene Calasanz, M.J.|||0000-0002-0374-3008 García-Sanz, Ramón|||0000-0003-4120-2787 Castro, Sergio Martínez-López, Joaquín|||0000-0001-7908-0063 Rodriguez-Otero, Paula|||0000-0001-5236-7785 González-Calle, Verónica|||0000-0002-5493-6707 González, Marta S. Oriol, Albert|||0000-0001-6804-2221 Gutierrez, Norma|||0000-0001-5834-9510 Ríos-Tamayo, Rafael|||0000-0001-8193-1402 Rosiñol, Laura|||0000-0002-2534-9239 Álvarez, Miguel Ángel Bargay, Joan|||0000-0002-6739-3916 Gonzalez-Rodriguez, Ana P. Alegre, Adrian|||0000-0002-2423-822X Escalante, Fernando|||0000-0003-4501-9066 Iñigo Rodríguez, María Belén de la Rubia, Javier|||0000-0002-8354-768X Teruel, Ana Isabel|||0000-0003-1559-7607 De Arriba, Felipe|||0000-0002-4451-1318 Palomera, Luis|||0000-0003-0359-7191 Hernández, Miguel Teodoro|||0000-0002-6576-7881 López-Jiménez, Javier Reinoso, Marta García-Mateo, Aránzazu Ocio, Enrique M.|||0000-0002-5765-0085 Bladé Creixenti, Juan|||0000-0002-4563-3405 Lahuerta, J. J.|||0000-0002-3393-9570 Cedena, María Teresa|||0000-0001-5851-3720 Paiva, Bruno|||0000-0003-1977-3815 San Miguel, Jesús F. Mateos, M. V.|||0000-0003-2390-1218 |
| author_role |
author |
| author2 |
Agulló, Cristina Contreras, Teresa Pérez, José Juan Aires, Irene Calasanz, M.J.|||0000-0002-0374-3008 García-Sanz, Ramón|||0000-0003-4120-2787 Castro, Sergio Martínez-López, Joaquín|||0000-0001-7908-0063 Rodriguez-Otero, Paula|||0000-0001-5236-7785 González-Calle, Verónica|||0000-0002-5493-6707 González, Marta S. Oriol, Albert|||0000-0001-6804-2221 Gutierrez, Norma|||0000-0001-5834-9510 Ríos-Tamayo, Rafael|||0000-0001-8193-1402 Rosiñol, Laura|||0000-0002-2534-9239 Álvarez, Miguel Ángel Bargay, Joan|||0000-0002-6739-3916 Gonzalez-Rodriguez, Ana P. Alegre, Adrian|||0000-0002-2423-822X Escalante, Fernando|||0000-0003-4501-9066 Iñigo Rodríguez, María Belén de la Rubia, Javier|||0000-0002-8354-768X Teruel, Ana Isabel|||0000-0003-1559-7607 De Arriba, Felipe|||0000-0002-4451-1318 Palomera, Luis|||0000-0003-0359-7191 Hernández, Miguel Teodoro|||0000-0002-6576-7881 López-Jiménez, Javier Reinoso, Marta García-Mateo, Aránzazu Ocio, Enrique M.|||0000-0002-5765-0085 Bladé Creixenti, Juan|||0000-0002-4563-3405 Lahuerta, J. J.|||0000-0002-3393-9570 Cedena, María Teresa|||0000-0001-5851-3720 Paiva, Bruno|||0000-0003-1977-3815 San Miguel, Jesús F. Mateos, M. V.|||0000-0003-2390-1218 |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universitat Autònoma de Barcelona |
| dc.subject.none.fl_str_mv |
Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Female Humans Male Mass Spectrometry Middle Aged Multiple Myeloma Myeloma Proteins Neoplasm, Residual Prognosis Smoldering Multiple Myeloma Treatment Outcome |
| topic |
Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Female Humans Male Mass Spectrometry Middle Aged Multiple Myeloma Myeloma Proteins Neoplasm, Residual Prognosis Smoldering Multiple Myeloma Treatment Outcome |
| description |
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have, therefore, investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance, detecting the M-protein by MS or clonal plasma cells by next-generation flow cytometry (NGF) identified cases with a significantly shorter median progression-free survival (mPFS) (MS: not reached vs. 1.4 years, P=0.001; NGF: not reached vs. 2 years, P=0.0002) but reaching complete response (CR) + stringent CR (sCR) did not discriminate between patients with different outcome. With NGF as a reference, the combined results of NGF and MS showed a high negative predictive value (NPV) of MS: 81% overall and 73% at treatment completion. When sequential results were considered, sustained negativity by MS or NGF was associated with a very favorable outcome with an mPFS not yet reached versus 1.66 years and 2.18 years in cases never attaining PRD or minimal residual disease (MRD) negativity, respectively. We can, thus, conclude that: 1) the standard response categories of the International Myeloma Working Group do not seem to be useful for monitoring treatment in HRsMM patients; 2) MS could be used as a valuable, non-invasive, clinical tool with the capacity of guiding timely bone marrow evaluations (based on its high NPV with NGF as a reference); and 3) similarly to NGF, sequential results of MS are able to identify a subgroup of HRsMM patients with long-term disease control. This study was registered at www.clinicaltrials.gov (clinicaltrials.gov identifier: 02415413). |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2 2024-01-01 2024 2024-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/311095 https://dx.doi.org/urn:doi:10.3324/haematol.2024.285742 |
| url |
https://ddd.uab.cat/record/311095 https://dx.doi.org/urn:doi:10.3324/haematol.2024.285742 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.relation.none.fl_str_mv |
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI21/01751 |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869424656458448896 |
| spelling |
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trialPuig, Noemí|||0000-0001-7535-3861Agulló, CristinaContreras, TeresaPérez, José JuanAires, IreneCalasanz, M.J.|||0000-0002-0374-3008García-Sanz, Ramón|||0000-0003-4120-2787Castro, SergioMartínez-López, Joaquín|||0000-0001-7908-0063Rodriguez-Otero, Paula|||0000-0001-5236-7785González-Calle, Verónica|||0000-0002-5493-6707González, Marta S.Oriol, Albert|||0000-0001-6804-2221Gutierrez, Norma|||0000-0001-5834-9510Ríos-Tamayo, Rafael|||0000-0001-8193-1402Rosiñol, Laura|||0000-0002-2534-9239Álvarez, Miguel ÁngelBargay, Joan|||0000-0002-6739-3916Gonzalez-Rodriguez, Ana P.Alegre, Adrian|||0000-0002-2423-822XEscalante, Fernando|||0000-0003-4501-9066Iñigo Rodríguez, María Belénde la Rubia, Javier|||0000-0002-8354-768XTeruel, Ana Isabel|||0000-0003-1559-7607De Arriba, Felipe|||0000-0002-4451-1318Palomera, Luis|||0000-0003-0359-7191Hernández, Miguel Teodoro|||0000-0002-6576-7881López-Jiménez, JavierReinoso, MartaGarcía-Mateo, AránzazuOcio, Enrique M.|||0000-0002-5765-0085Bladé Creixenti, Juan|||0000-0002-4563-3405Lahuerta, J. J.|||0000-0002-3393-9570Cedena, María Teresa|||0000-0001-5851-3720Paiva, Bruno|||0000-0003-1977-3815San Miguel, Jesús F.Mateos, M. V.|||0000-0003-2390-1218AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMass SpectrometryMiddle AgedMultiple MyelomaMyeloma ProteinsNeoplasm, ResidualPrognosisSmoldering Multiple MyelomaTreatment OutcomeThe value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have, therefore, investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance, detecting the M-protein by MS or clonal plasma cells by next-generation flow cytometry (NGF) identified cases with a significantly shorter median progression-free survival (mPFS) (MS: not reached vs. 1.4 years, P=0.001; NGF: not reached vs. 2 years, P=0.0002) but reaching complete response (CR) + stringent CR (sCR) did not discriminate between patients with different outcome. With NGF as a reference, the combined results of NGF and MS showed a high negative predictive value (NPV) of MS: 81% overall and 73% at treatment completion. When sequential results were considered, sustained negativity by MS or NGF was associated with a very favorable outcome with an mPFS not yet reached versus 1.66 years and 2.18 years in cases never attaining PRD or minimal residual disease (MRD) negativity, respectively. We can, thus, conclude that: 1) the standard response categories of the International Myeloma Working Group do not seem to be useful for monitoring treatment in HRsMM patients; 2) MS could be used as a valuable, non-invasive, clinical tool with the capacity of guiding timely bone marrow evaluations (based on its high NPV with NGF as a reference); and 3) similarly to NGF, sequential results of MS are able to identify a subgroup of HRsMM patients with long-term disease control. This study was registered at www.clinicaltrials.gov (clinicaltrials.gov identifier: 02415413).Universitat Autònoma de Barcelona 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/311095https://dx.doi.org/urn:doi:10.3324/haematol.2024.285742reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI21/01751open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3110952026-06-06T12:50:31Z |
| score |
15,811543 |